ClinicalTrials.gg
Not yet recruitingNCT07732205Updated Nov 18, 2026

Effects of Lokomat-Robot Assisted Gait Training on Gross Motor Function in Children and Young Adults With Cerebral Palsy

An interventional study of Sessions with Lokomat robot-assisted system and Control arm in Cerebral Palsy, sponsored by Semmelweis University. Not yet recruiting at 1 site in Hungary. Open to participants aged 3 Years to 23 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Semmelweis University · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
3 Years to 23 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Cerebral Palsy with a site in Hungary — 2 open to participants now, 3 under way, none of them phase 3. Cerebral Palsy · Hungary.

Started
2027
with 1 other
No phase
3 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
3 of 10
Semmelweis University

Among the 10 studies in Cerebral Palsy with a site in Hungary, this one is one of 2 that started in 2027, is one of 3 with no phase, and was the 9th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

2 of the 10 studies in Cerebral Palsy with a site in Hungary are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 273 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 238 (87%) stop at 75 or younger; 258 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 23 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cerebral Palsy with a site in Hungary, or all of them as a file.
02

Study summary

This single-center, controlled, delayed-intervention, quasi-experimental study evaluates the effectiveness of Lokomat®-assisted robotic gait training on gross motor function and health-related quality of life in children and young adults with cerebral palsy.

Although previous studies have reported improvements in walking ability, gross motor function, and lower limb performance following Lokomat-assisted gait training, uncertainty remains regarding the optimal treatment intensity and dosing schedule, particularly across different age groups and levels of functional impairment.

The primary objective of this study is to evaluate the effect of a 20-session (8 week) Lokomat-assisted gait training program on standing and walking function, assessed using Dimensions D and E of the Gross Motor Function Measure (GMFM-88). Secondary objectives include evaluation of lower limb muscle strength, walking speed, health-related quality of life, individualized rehabilitation goal attainment, and objective gait training parameters recorded by the Lokomat® system.

The study employs a controlled, delayed-intervention, quasi-experimental design conducted over three consecutive study periods. During each study period, one intervention group receives Lokomat-assisted gait training in addition to usual rehabilitation, whereas a concurrent control group receives usual rehabilitation alone. As standard (usual) rehabilitation participants receive nationally approved standard-of-care rehabilitation, which may include neurorehabilitation, physiotherapy, and/or educational (pedagogical) rehabilitation, as appropriate to their individual clinical needs and routine care.

After completion of the control period and post-intervention assessment, participants in the control group receive the same 20-session Lokomat-assisted gait training program and physiotherapy program during the subsequent study period. Participants allocated to the control group during the final study period receive the intervention after completion of the formal study period.

Read the detailed description

Motor learning theory and contemporary neurorehabilitation emphasize that intensive, task-specific, repetitive practice is essential for promoting neuroplasticity and improving functional motor performance in individuals with neurological disorders. Robot-assisted gait training has therefore become an increasingly important component of pediatric neurorehabilitation by enabling highly repetitive, standardized, and individualized gait practice while reducing the physical burden on therapists.

The Lokomat® robotic gait orthosis combines body-weight-supported treadmill training with computer-controlled lower limb guidance, allowing precise adjustment of walking speed, robotic assistance, and body-weight support according to each participant's functional abilities. Previous studies have demonstrated beneficial effects of Lokomat-assisted gait training on gait performance, gross motor function, endurance, and lower limb function in children with cerebral palsy. However, the available literature shows considerable variability regarding intervention frequency, treatment intensity, total number of sessions, and participant characteristics. Consequently, no consensus currently exists regarding the optimal therapeutic dose for different age groups and functional severity levels.

The intervention dose selected for the present study consists of 20 treatment sessions delivered over approximately eight weeks. This treatment schedule was determined based on two complementary considerations. First, it reflects the clinical experience of this treatment intensity has proven feasible and well tolerated in routine clinical practice. Second, the selected dose is consistent with the range of intervention protocols most frequently reported in published pediatric Lokomat studies, thereby allowing comparison of the present findings with the existing literature while evaluating the practical applicability of this protocol in a real-world rehabilitation setting.

Study Objectives

The primary objective of this study is to evaluate the effectiveness of Lokomat-assisted robotic gait training on standing and walking function in children and young adults with cerebral palsy.

In addition, the study aims to determine whether treatment tolerance and clinical effectiveness differ according to participants' age and functional severity as classified by the Gross Motor Function Classification System (GMFCS). An important objective is to explore whether treatment response differs according to functional severity and age and to provide evidence for the development of a standardized clinical protocol for Lokomat-assisted rehabilitation within pediatric neurorehabilitation.

The study also investigates whether participation in conductive education influences rehabilitation outcomes following robot-assisted gait training.

Study Design

This is a single-center, controlled, delayed-intervention, quasi-experimental study conducted over three consecutive study periods. Participants are enrolled according to the routine admission schedule and allocated to either an intervention group or a concurrent control group.

Participants in the intervention group receive a 20-session Lokomat-assisted gait training program in addition to their usual rehabilitation. Participants in the control group continue their usual rehabilitation during the control period and subsequently receive the same Lokomat-assisted intervention after completion of the post-control assessment. Participants assigned to the final control group receive the intervention after completion of the formal study period, ensuring that all eligible participants have access to robotic gait training.

Approximately 96 participants with cerebral palsy are expected to be enrolled.

Outcome assessments are performed before and after each study period and include evaluation of standing and walking function using the GMFM-88 Dimensions D and E, lower limb muscle strength, walking speed, health-related quality of life, Goal Attainment Scaling (GAS), and objective gait training parameters recorded by the Lokomat® system. Functional severity is classified using the Gross Motor Function Classification System (GMFCS).

03

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • rehabilitation
  • cerebral palsy
  • robot-assisted therapy
  • conductive education
  • lokomat
  • robot-assisted gait training
  • pediatric neurorehabilitation
  • gross motor function
  • walking function
  • health-related quality of life
  • gross motor function measure
  • goal attainment scaling
04

Who can participate

Ages eligible
3 Years to 23 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and young adult with cerebral palsy (GMFCS II-IV)
  • Age between 3-23 years, of both genders
  • Minimum length of femur: 21 centimeters
  • Hip X-ray not older than 3 months
  • Orthopedic specialist opinion and recommendation for robotic therapy treatment not older than one month
  • Valid medical referral for robotic therapy treatment
  • Signed consent form from the parent/custodian

Exclusion criteria

Exclusion Criteria:

  • Gross motor function classification GMFCS I or GMFCS V
  • Participation in robotic therapy at another location during the control group
  • The safety regulations and specified by the manufacturer are fully taken into account when using the Lokomat® robotic-assisted gait training system used in the study
  • The main contraindications for the use of Lokomat® include:
  • significant bone mineral density loss (osteopenia, osteoporosis) and increased fracture risk;
  • unhealed or unstable bone fractures; fixed joint contractures that significantly limit the range of motion;
  • medical conditions that prevent active rehabilitation participation (e.g. acute infection, severe respiratory or cardiovascular condition, significant cognitive or neuropsychological impairment);
  • anatomical or body size differences that prevent safe use of the device;
  • skin or soft tissue lesions that pose a risk of injury during use of the orthosis or suspension system.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    In this group, participants received robot-assisted therapy and their usual rehabilitation. During the 8 weeks period, participants will accomplish 20 sessions by using the Lokomat robotic gait training system and participate in physiotherapy sessions.

    Device: Sessions with Lokomat robot-assisted system

  • Active comparator
    Control Arm

    In this group, participants received usual rehabilitation (e.g. conductive education, physiotherapy). Participants in this group accomplished 20 sessions during 8 weeks by using the Lokomat robotic gait training system and participate in physiotherapy.

    Other: Control arm

Interventions

  • DeviceSessions with Lokomat robot-assisted system

    During the intervention, participants accomplish rehabilitation sessions by using Lokomat robotic gait training system. Each participant will participate in robot-assisted rehabilitation and physiotherapy 5 times in two weeks, 20 times total during the 8 week period of rehabilitation. The robot-assisted rehabilitation session lasts approximately 60 minutes, depends on the individual needs and performance.

  • OtherControl arm

    Participants continue their usual rehabilitation without Lokomat -assisted gait training during the control period.

06

What researchers measure

Primary outcomes

  1. Standing and walking functions

    The Gross Motor Function Measure-88 (GMFM-88) is a validated observational outcome measure specifically developed to assess gross motor function in children with cerebral palsy. The study evaluates Dimensions D (Standing; 13 items) and E (Walking, Running, and Jumping; 24 items). Each item is scored on a 4-point ordinal scale (0 = does not initiate the task, 1 = initiates, 2 = partially completes, 3 = completes the task). Raw scores are converted to percentage scores ranging from 0% to 100% for each dimension. The Dimension D and E percentage scores (0-100%) will be analyzed as continuous variables and summarized using mean and standard deviation (SD). Higher scores indicate better gross motor function.

    Time frame: Measurement at 0 weeks and 8 weeks

Secondary outcomes

  1. Lower limb muscle strength

    Change in lower limb muscle strength assessed using a handheld dynamometer. Muscle strength will be measured in Newtons (N)/kilograms-force \[kgf\] during standardized maximal voluntary isometric contractions of predefined lower limb muscle groups. Three trials will be performed for each muscle group, and the highest value will be used for analysis. The primary outcome will be the change in muscle strength from baseline to the post-intervention assessment. Results will be summarized as mean ± standard deviation and compared between study groups using appropriate statistical methods.

    Time frame: Measurement at 0 weeks, 8 weeks

  2. Goal attainment

    Goal Attainment Scaling (GAS) is a personalized outcome measure used in clinical and rehabilitation settings to track a patient's progress toward individualized goals. It allows patients and practitioners to collaboratively set specific targets and translate qualitative improvements into standardized numerical scores for statistical evaluation. Each goal will be rated on a 5-point scale ranging from -2 (baseline or much less than expected outcome) to +2 (much better than expected outcome), with 0 representing the expected level of achievement after the intervention. Individual goal scores will be converted into a standardized GAS T-score (mean = 50, standard deviation = 10) when appropriate. Changes in GAS scores from baseline to the post-intervention assessment will be summarized using mean ± standard deviation and compared between study groups using appropriate statistical methods.

    Time frame: Measurement at 0 weeks and 8 weeks

  3. Functional performance changes measured by walking speed

    Walking speed will be assessed using the 10-Meter Walk Test (10MWT), a validated and reliable measure of gait performance. Participants will be instructed to walk at their self-selected comfortable walking speed along a standardized walkway. The time required to complete the test will be recorded in seconds, and walking speed will be calculated in meters per second (m/s). Changes in walking speed from baseline to the post-intervention assessment will be analyzed. Results will be summarized using mean and standard deviation (SD).

    Time frame: Measurement at 0 weeks and 8 weeks.

  4. Changes in training parameters recorded by the Lokomat system

    Objective gait training parameters will be automatically recorded by the Lokomat system during the first and last treatment sessions. Recorded parameters will include walking distance (m), average walking speed (km/h), and robotic assistance level (% body weight support and/or guidance force, depending on the Lokomat settings). Changes in these parameters from baseline to the final treatment session will be analyzed. Results will be summarized as mean ± standard deviation and compared within and between study groups using appropriate statistical methods.

    Time frame: Measurement at 0 weeks and 8 weeks.

  5. Health-related quality of life

    Health-related quality of life (HRQoL) will be assessed using the Pediatric Quality of Life Inventory (PedsQL™) Scales, selecting the age-appropriate version for each participant. The questionnaire will be administered at baseline and at the post-intervention assessment. For participants 2-4 years of age, the parent-proxy report will be completed by the parent or primary caregiver. For children 5-7 years of age, both the child self-report and the parent-proxy report will be obtained. Participants 8-12 years and 13-23 years will complete the age-appropriate child/adolescent self-report, while a corresponding parent-proxy report will also be collected. The PedsQL Generic Core Scales assess four domains of health-related quality of life: physical functioning, emotional functioning, social functioning, and school functioning.The total score will be analyzed as continuous variables. Results will be summarized using mean and standard deviation (SD).

    Time frame: Measurement at 0 weeks and 8 weeks.

07

Study locations

1 site
  • Semmelweis University, András Pető Rehabilitation and Health Care Department, Institutions of Conductive Pedagogical Center
    Budapest, Pest County 1125, Hungary
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2027, 7 months later.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 7 months is below that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartEst.
Jan 31, 2027was Aug 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 31, 2026→Jan 31, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Aug 31, 2026→Jan 31, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07732205
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jan 31, 2027 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion